{"url_path":"/sec/clrb/8-k/2026-05-08/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","accession_number":"0001104659-26-057460","cik":"0001279704","ticker":"CLRB","issuer_name":"Cellectar Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","primary_entity_key":"0001279704","primary_entity_name":"Cellectar Biosciences, Inc."},"word_count":295,"has_tables":true,"body_markdown":"false\n0001279704\n\n0001279704\n\n2026-05-04\n2026-05-04\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington, DC 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities\nExchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\nMay 4, 2026\n\n \n\n \n\n**Cellectar Biosciences, Inc.**\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n \n\nDelaware \n1-36598 \n04-3321804\n\n(State or Other Jurisdiction\n\nof Incorporation)** **\n(Commission File Number)** **\n(I.R.S. Employer Identification\n\nNumber)\n\n \n\n**100\nCampus Drive, Florham Park, NJ, 07932**\n\n(Address of Principal Executive Offices) (Zip\nCode)\n\n \n\n**(608) 441-8120**\n\n(Registrant’s Telephone Number, Including Area Code)\n\n \n\n**Not Applicable**\n\n(Former Name or Former Address, if Changed\nSince Last Report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n \nTrading\n\nSymbol(s)\n \nName\nof each exchange on which\n\nregistered\n\nCommon Stock, par value $0.00001 per share\n \nCLRB\n \nNASDAQ\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange\nAct of 1934.\n\n \n\n¨ Emerging\ngrowth company\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}